A Phase 3 interventional study of Follitropin Delta (FE 999049) and Follitropin Alfa (GONAL-F) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 12 sites in India. Open to female participants aged 21 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 9th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 21 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2021.
This study's enrollment of 220 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 11 in phase 3, and was the 31st registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
Drug: Follitropin Delta (FE 999049)
rFSH. Follitropin alfa for subcutaneous injection
Drug: Follitropin Alfa (GONAL-F)
FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose was 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose was on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose was fixed throughout the stimulation period and maximum allowed daily dose was 12 μg. Participants could be treated for a maximum of 20 days.
Also known as: REKOVELLE
GONAL-F was administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 450 IU. Participants could be treated for a maximum of 20 days.
Also known as: GONAL-F
Ongoing pregnancy rate
Ongoing pregnancy is defined as at least one intrauterine viable fetus 10-11 weeks after embryo transfer.
Time frame: 10-11 weeks after embryo transfer
Positive beta human chorionic gonadotropin (βhCG) rate
Positive βhCG is defined as positive serum βhCG test 13-15 days after embryo transfer.
Time frame: 13-15 days after embryo transfer
Clinical pregnancy rate
Clinical pregnancy is defined as at least one gestational sac 5-6 weeks after embryo transfer.
Time frame: 5-6 weeks after embryo transfer
Vital pregnancy rate
Vital pregnancy is defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after embryo transfer.
Time frame: 5-6 weeks after embryo transfer
Implantation rate
Implantation rate is defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.
Time frame: 5-6 weeks after embryo transfer
Ongoing implantation rate
Ongoing implantation rate is defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of embryos transferred.
Time frame: 10-11 weeks after embryo transfer
Proportion of subjects with extreme ovarian responses
Extreme ovarian response is defined as \<4, ≥15 or ≥20 oocytes retrieved.
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Proportion of subjects with early ovarian hyperstimulation syndrome (OHSS) (including OHSS of moderate/severe grade) and/or preventive interventions for early OHSS
The proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS will be presented.
Time frame: ≤9 days after triggering of final follicular maturation
Proportion of subjects with cycle cancellation due to poor or excessive ovarian response or embryo transfer cancellation due to excessive ovarian response / OHSS risk
The proportion of participants with cycle cancellation due to poor or excessive ovarian response or embryo transfer cancellation due to excessive ovarian response / OHSS risk will be presented.
Time frame: At end-of-stimulation (up to 20 stimulation days) or transfer visit
Number of follicles on stimulation Day 6
Counted by ultrasound for the right and left ovary.
Time frame: On stimulation Day 6
Number of follicles at end-of-stimulation
Counted by ultrasound for the right and left ovary.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Size of follicles on stimulation Day 6
Measured by ultrasound for the right and left ovary.
Time frame: On stimulation Day 6
Size of follicles at end-of-stimulation
Measured by ultrasound for the right and left ovary.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Number of oocytes retrieved
The number of oocytes retrieved will be recorded at the oocyte retrieval visit.
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Proportion of subjects with <4, 4-7, 8-14, 15-19 and ≥20 oocytes retrieved
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Percentage of metaphase II oocytes (only applicable for those inseminated using intracytoplasmic sperm injection [ICSI])
The percentage of metaphase II oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI will be presented.
Time frame: On day of oocyte retrieval (up to 22 days after stimulation)
Fertilisation rate
The fertilisation rate is defined as the number of fertilized oocytes with 2 pronuclei divided by the number of oocytes retrieved.
Time frame: On Day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Number and quality of embryos on day 3 after oocyte retrieval
The total number of embryos and the number of good-quality embryos will be counted on Day 3. A good-quality embryo is defined as an embryo with ≥6 blastomeres and ≤20% fragmentation, without signs of multinucleation.
Time frame: On Day 3 after oocyte retrieval (up to 25 days after start of stimulation)
Circulating concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
Blood samples for analysis of circulating concentrations of FSH and LH will be drawn.
Time frame: On stimulation day 6
Circulating concentrations of estradiol
Blood samples for analysis of circulating concentrations of estradiol will be drawn.
Time frame: On stimulation day 6
Circulating concentrations of progesterone
Blood samples for analysis of circulating concentrations of progesterone will be drawn.
Time frame: On stimulation day 6
Circulating concentrations of inhibin A and inhibin B
Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn.
Time frame: On stimulation day 6
Circulating concentrations of FSH and LH
Blood samples for analysis of circulating concentrations of FSH and LH will be drawn.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Circulating concentrations of estradiol
Blood samples for analysis of circulating concentrations of estradiol will be drawn.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Circulating concentrations of progesterone
Blood samples for analysis of circulating concentrations of progesterone will be drawn.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Circulating concentrations of inhibin A and inhibin B
Blood samples for analysis of circulating concentrations of inhibin A and inhibin B will be drawn.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Total gonadotropin dose
The total gonadotropin dose will be recorded.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Number of stimulation days
Time frame: At end-of-stimulation (up to 20 stimulation days)
Proportion of subjects with investigator-requested gonadotropin dose adjustments
The decreases and increases of the gonadotropin dose will be captured during the stimulation period.
Time frame: From stimulation Day 6 to end-of-stimulation (up to 20 stimulation days)
Number of events and intensity of adverse events
Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)
Changes from baseline in circulating levels of clinical chemistry parameters: Albumin and Total protein
Blood samples will be collected for the analysis of clinical chemistry parameters including: Albumin and Total protein.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical chemistry parameters: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase, Gamma-glutamyl transpeptidase
Blood samples will be collected for the analysis of clinical chemistry parameters including: Alanine transaminase, Alkaline phosphatase, Aspartate aminotransferase and Gamma-glutamyl transpeptidase.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical chemistry parameters: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium, Uric acid
Blood samples will be collected for the analysis of clinical chemistry parameters including: Bicarbonate, Blood urea nitrogen, Calcium, Chloride, Cholesterol total, Glucose, Phosphorus, Potassium, Sodium and Uric acid.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical chemistry parameters: Bilirubin direct, Bilirubin, Creatinine
Blood samples will be collected for the analysis of clinical chemistry parameters including: Bilirubin direct, Bilirubin and Creatinine.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical chemistry parameters: Lactate dehydrogenase
Blood samples will be collected for the analysis of clinical chemistry parameter including: Lactate dehydrogenase.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-stimulation
Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Proportion of subjects with markedly abnormal changes from baseline in clinical chemistry at end-of-trial
Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) will be reported. The clinical chemistry parameters include: albumin, alanine transaminase, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.
Time frame: At end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: Red blood cells, Red blood cells morphology
Blood samples will be collected for the analysis of clinical haematology including: Red blood cells and Red blood cell morphology.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: White blood cells, White blood cell morphology, Platelets
Blood samples will be collected for the analysis of clinical haematology including: White blood cells, White blood cell morphology and Platelets.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: Haemoglobin
Blood samples will be collected for the analysis of clinical haematology parameter including: Haemoglobin.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: Haematocrit
Blood samples will be collected for the analysis of clinical haematology parameter including: Haematocrit.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Volume
Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Volume.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Haemoglobin
Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Haemoglobin.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Changes from baseline in circulating levels of clinical haematology parameters: Mean Corpuscular Hemoglobin Concentration
Blood samples will be collected for the analysis of clinical haematology parameter including: Mean Corpuscular Hemoglobin Concentration.
Time frame: From screening up to end-of-trial (up to approximately 5.5 months)
Proportion of subjects with markedly abnormal changes from baseline in haematology parameters at end-of-stimulation
Defined as number of participants with at least one markedly abnormal changes in haematology parameters (as assessed by investigator) will be reported. Haematology parameters include: red blood cells, red blood cell morphology, white blood cells, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Proportion of subjects with markedly abnormal changes from baseline in haematology parameters end-of-trial
Defined as number of participants with at least one markedly abnormal changes in haematology parameters (as assessed by investigator) will be reported. Haematology parameters include: red blood cells, red blood cell morphology, white blood cells, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.
Time frame: At end-of-trial (up to approximately 5.5 months)
Frequency of injection site reactions (redness, pain, itching, swelling and bruising)
Assessed by the participant during the stimulation period. Participants will self-assess injection site reactions (redness, pain, itching, swelling, and bruising) immediately, 30 minutes and 24 hours after each injection.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Intensity of injection site reactions
Assessed by the participant during the stimulation period as mild, moderate or severe. Participants will be tabulated according to the highest severity of their reported injection site reactions.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Frequency of immune-related adverse events
All adverse events reported in the trial will be analyzed to identify those that are potentially immune-related. They will be tabulated using the Standardised Medical Dictionary for Regulatory Activities \[MedDRA\] Queries (SMQs).
Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)
Intensity of immune-related adverse events
Will be categorised as mild, moderate or severe.
Time frame: From signing of the informed consent up to end-of-trial (approximately 5.5 months)
Proportion of subjects with cycle cancellations due to an adverse event, including immune-related adverse events, or due to technical malfunctions of the pre-filled injection pen
For each participant the reason for cycle cancellation will be recorded.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Proportion of subjects with late OHSS (including OHSS of moderate/severe grade)
Late OHSS is defined as OHSS with onset \>9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade will be presented.
Time frame: >9 days after triggering of final follicular maturation
Proportion of subjects with OHSS (early and/or late) and/or preventive interventions for early OHSS
The proportion of participants with early and/or late OHSS and/or preventive interventions for early OHSS will be presented.
Time frame: >9 days after triggering of final follicular maturation
Percentage of subjects with multi-fetal gestation, biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins
The percentage of participants with each of these events will be reported.
Time frame: 10-11 weeks after transfer
Technical malfunctions of the pre-filled injection pen
Participants will report any technical malfunctions of the pre-filled injection pen. Percentage of participants with confirmed technical malfunctions will be presented.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Dec 2023, 24 months.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 24 months is above that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Follitropin delta · Follitropin alfa